TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC - 101967

Spotlight
Video

TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC

Loading........
Description: Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at the 2018 Gastrointestinal Cancers Symposium.
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/26/18
Added : 6 months ago